Safety and efficacy of human platelet extract in skin recovery after fractional CO 2 laser resurfacing of the face: A randomized, controlled, evaluator‐blinded pilot study
Journal of Cosmetic Dermatology · 2023
DOI: 10.1111/jocd.15914 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2023. Verfasst von Steven Dayan und 7 weiteren Autor:innen. Beteiligte Einrichtung: DeNova Research, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Laser Therapy, Lasers, Gas, Skin Aging. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rion Aesthetics.
Abstract (Originalsprache)
Background
Fractional carbon dioxide (CO 2 ) laser resurfacing is used successfully for facial rejuvenation. Post procedure skincare is a variable that influences downtime caused by pain/tenderness, erythema, crusting, and bruising.
Aims
The primary objective of this pilot study was to demonstrate the benefits of human platelet extract (HPE) (plated)™ CALM Serum, a new topical cosmetic product, following fractionated CO 2 ablative laser resurfacing treatment to the entire face versus standard of care.
Methods
In a single‐center, randomized, evaluator‐blinded pilot study, a total of 18 subjects were randomized into two groups, CO 2 facial resurfacing followed by post‐procedural standard of care (Stratacel silicone gel) or CO 2 facial resurfacing with the addition of HPE renewosomes in the CALM Serum.
Results
CALM Serum demonstrated statistically significant less crusting at Day 10 compared to the control group ( p = 0.0193) with less downtime in the first 14 days ( p = 0.03). Subjects treated with CALM Serum had statistically significant brighter appearing skin at 14 days ( p = 0.007) and more youthful looking skin on Days 14 and 30 ( p = 0.003 and 0.04, respectively).
Conclusions
This study demonstrates that Renewosome™ technology provides statistically significant post‐laser clinical recovery over silicone gel for reducing crusting, and downtime. Subjects reported less diary days of symptoms of pain/tenderness, redness, crusting/flaking, bruising, and itching in the first 14 days compared to the control group. CALM also demonstrated statistically significant improvements in brighter and more youthful appearing skin. CALM is safe and well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- DeNova Research, Chicago, Illinois, USA.
- University of Illinois, Chicago, Illinois, USA.
- UltaMed Corporation, Fort Lauderdale, Florida, USA.
- Boulder Biostatistics, Steamboat Springs, Colorado, USA.
- Rion Aesthetics, Rochester, Minnesota, USA.
- Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Nimit Gandhi, Chris Paradise
Förderung
- Rion Aesthetics
Zitieren
APA
Dayan, S., Gandhi, N., Wilson, J., Kola, E., Jankov, L. E., Copeland, K., Paradise, C., & Behfar, A. (2023). Safety and efficacy of human platelet extract in skin recovery after fractional CO 2 laser resurfacing of the face: A randomized, controlled, evaluator‐blinded pilot study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.15914
Vancouver
Dayan S, Gandhi N, Wilson J, Kola E, Jankov LE, Copeland K, et al. Safety and efficacy of human platelet extract in skin recovery after fractional CO 2 laser resurfacing of the face: A randomized, controlled, evaluator‐blinded pilot study. Journal of Cosmetic Dermatology. 2023. doi:10.1111/jocd.15914
BibTeX
@article{Dayan2023,
author = {Dayan, Steven and Gandhi, Nimit and Wilson, John and Kola, Eljona and Jankov, Laura Eaton and Copeland, Karen and Paradise, Chris and Behfar, Atta},
title = {Safety and efficacy of human platelet extract in skin recovery after fractional CO 2 laser resurfacing of the face: A randomized, controlled, evaluator‐blinded pilot study},
journal = {Journal of Cosmetic Dermatology},
year = {2023},
doi = {10.1111/jocd.15914}
}
EUVIMED